Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Ankylosing spondylitis:

Myocardial dysfunction in ankylosing spondylitis. Gould BA et al. Ann Rheum Dis. (1992)

Ankylosing spondylitis: an autoimmune disease? Lakomek HJ et al. Ann Rheum Dis. (1991)

HLA B27 and the genetics of ankylosing spondylitis. Woodrow JC et al. Ann Rheum Dis. (1978)

Search results

Items: 1 to 20 of 18140

1.

An Update on Diagnosis and Classification of Axial Spondyloarthritis.

Navarro-Compán V.

Curr Rheumatol Rep. 2019 Jun 15;21(8):39. doi: 10.1007/s11926-019-0838-5. Review.

PMID:
31203462
2.

Secukinumab immunogenicity over 52 weeks in patients with psoriatic arthritis and ankylosing spondylitis.

Deodhar A, Gladman DD, McInnes IB, Spindeldreher S, Martin R, Pricop L, Porter B, Safi J Jr, Shete A, Bruin G.

J Rheumatol. 2019 Jun 15. pii: jrheum.190116. doi: 10.3899/jrheum.190116. [Epub ahead of print]

PMID:
31203228
3.

Secukinumab induced Behçet's syndrome: a report of two cases.

Dincses E, Yurttas B, Esatoglu SN, Melikoglu M, Hamuryudan V, Seyahi E.

Oxf Med Case Reports. 2019 May 31;2019(5):omz041. doi: 10.1093/omcr/omz041. eCollection 2019 May.

4.

Confounding of linkage disequilibrium patterns in large scale DNA based gene-gene interaction studies.

Joiret M, Mahachie John JM, Gusareva ES, Van Steen K.

BioData Min. 2019 Jun 10;12:11. doi: 10.1186/s13040-019-0199-7. eCollection 2019.

5.

ILC3 in Axial Spondyloarthritis: the Gut Angle.

Mauro D, Macaluso F, Fasano S, Alessandro R, Ciccia F.

Curr Rheumatol Rep. 2019 Jun 13;21(7):37. doi: 10.1007/s11926-019-0834-9. Review.

PMID:
31197599
6.

IgG Galactosylation status combined with MYOM2-rs2294066 precisely predicts anti-TNF response in ankylosing spondylitis.

Liu J, Zhu Q, Han J, Zhang H, Li Y, Ma Y, He D, Gu J, Zhou X, Reveille JD, Jin L, Zou H, Ren S, Wang J.

Mol Med. 2019 Jun 13;25(1):25. doi: 10.1186/s10020-019-0093-2.

PMID:
31195969
7.

Biologic Response Modifiers (BRMs).

Sapkota B, Makandar SN.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan-.
2019 May 30.

8.

Detecting T cell receptors involved in immune responses from single repertoire snapshots.

Pogorelyy MV, Minervina AA, Shugay M, Chudakov DM, Lebedev YB, Mora T, Walczak AM.

PLoS Biol. 2019 Jun 13;17(6):e3000314. doi: 10.1371/journal.pbio.3000314. [Epub ahead of print]

9.

[Pregnancy outcomes in Icelandic female patients with inflammatory arthritides. Nationwide results from the ICEBIO and the Icelandic Medical Birth Register].

Kristjansdottir SR, Steingrimsdottir T, Grondal G, Bjarnadóttir RI, Einarsdottir K, Gudbjornsson B.

Laeknabladid. 2019 Juni;105(6):267-275. doi: doi.org/10.17992/lbl.2019.06.235. Icelandic.

PMID:
31192789
10.

Prevalence of metabolic syndrome and its associated factors in Chinese patients with ankylosing spondylitis [Corrigendum].

Liu M, Huang Y, Huang Z.

Diabetes Metab Syndr Obes. 2019 May 22;12:729. doi: 10.2147/DMSO.S212730. eCollection 2019. No abstract available.

11.

Core stability and balance in patients with ankylosing spondylitis.

Acar Y, Ilçin N, Gürpinar B, Can G.

Rheumatol Int. 2019 Jun 12. doi: 10.1007/s00296-019-04341-5. [Epub ahead of print]

PMID:
31190088
12.

A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501.

Markus R, McBride HJ, Ramchandani M, Chow V, Liu J, Mytych D, Fanjiang G.

Adv Ther. 2019 Jun 10. doi: 10.1007/s12325-019-00979-6. [Epub ahead of print] Review.

PMID:
31183781
13.

Factors associated with disease-specific quality of life in Taiwanese patients with ankylosing spondylitis: a cross-sectional study.

Lu MC, Huang KY, Tung CH, Hsu BB, Wu CH, Koo M, Lai NS.

BMJ Open. 2019 Jun 9;9(6):e028966. doi: 10.1136/bmjopen-2019-028966.

14.

Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases.

Papamichael K, Vogelzang E, Lambert J, Wolbink G, Cheifetz AS.

Expert Rev Clin Immunol. 2019 Jun 14:1-12. doi: 10.1080/1744666X.2019.1630273. [Epub ahead of print]

PMID:
31180729
15.

Comparison of HLA-B*27 subtypes between Chinese patients with ankylosing spondylitis and non-ankylosing spondylitis carriers.

Luo F, Zhao Z, Zhang J, Leng J.

J Int Med Res. 2019 Jun 10:300060519853929. doi: 10.1177/0300060519853929. [Epub ahead of print]

PMID:
31177886
16.

Spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison.

Braun J, Haibel H, de Hooge M, Landewé R, Rudwaleit M, Fox T, Readie A, Richards HB, Porter B, Martin R, Poddubnyy D, Sieper J, van der Heijde D.

Arthritis Res Ther. 2019 Jun 7;21(1):142. doi: 10.1186/s13075-019-1911-1.

17.

Heart Involvement in Inflammatory Rheumatic Diseases: A Systematic Literature Review.

Buleu F, Sirbu E, Caraba A, Dragan S.

Medicina (Kaunas). 2019 Jun 6;55(6). pii: E249. doi: 10.3390/medicina55060249. Review.

19.

Adverse events in patients with ankylosing spondylitis treated with TNF inhibitors: a cross-sectional study.

Wroński J, Fiedor P, Głuszko P.

Int J Clin Pharm. 2019 Jun 6. doi: 10.1007/s11096-019-00859-7. [Epub ahead of print]

PMID:
31172410
20.

Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis.

Reis J, Vender R, Torres T.

BioDrugs. 2019 Jun 6. doi: 10.1007/s40259-019-00361-6. [Epub ahead of print] Review.

PMID:
31172372

Supplemental Content

Loading ...
Support Center